MedTrace Logo

Study in Adult Subjects Undergoing Posterolateral Thoracotomy

NCT03428984 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2019-02-06

No results posted yet for this study

Summary

Primary Objective: To characterize the pharmacokinetic (PK) profile of EXPAREL when administered as a posterior intercostal nerve block.

Secondary Objective: To assess the safety and tolerability of EXPAREL in this surgical model.

Conditions

  • Postoperative Pain Management

Interventions

DRUG

EXPAREL

EXAPREL 266 mg in 20 mL

Sponsors & Collaborators

  • Pacira Pharmaceuticals, Inc

    lead INDUSTRY

Principal Investigators

  • David Rice, MD · MD Anderson

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-03
Primary Completion
2018-09-28
Completion
2018-09-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03428984 on ClinicalTrials.gov